Idiopathic pulmonary fibrosis: an update on pathogenesis
Q Mei, Z Liu, H Zuo, Z Yang, J Qu - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …
Idiopathic pulmonary fibrosis: an update
P Spagnolo, N Sverzellati, G Rossi, A Cavazza… - Annals of …, 2015 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …
Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
DS Glass, D Grossfeld, HA Renna, P Agarwala… - Respiratory …, 2020 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …
Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives
M Kreuter, F Bonella, M Wijsenbeek… - BioMed research …, 2015 - Wiley Online Library
Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …
Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis
H Ma, X Wu, Y Li, Y Xia - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …
[HTML][HTML] A review of current and novel therapies for idiopathic pulmonary fibrosis
R Rafii, MM Juarez, TE Albertson… - Journal of thoracic …, 2013 - ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is
associated with a median survival of 2-3 years from initial diagnosis. To date, there is no …
associated with a median survival of 2-3 years from initial diagnosis. To date, there is no …
Idiopathic pulmonary fibrosis: new insights in its pathogenesis
Idiopathic pulmonary fibrosis (IPF) is a unique type of chronic fibrosing lung disease of
unknown etiology. The sequence of the pathogenic mechanisms is unknown, but the …
unknown etiology. The sequence of the pathogenic mechanisms is unknown, but the …
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
H Loomis-King, KR Flaherty, BB Moore - Current opinion in pharmacology, 2013 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) of unknown
origin characterized by epithelial cell dysfunctions, accumulation of fibroblasts and …
origin characterized by epithelial cell dysfunctions, accumulation of fibroblasts and …